Interim Report Q3 2024

The Board and CEO of Eevia Health Plc present the Interim financial report for quarter 3, 2024.
 

Financial developments and significant events in the third quarter of 2024:

· Net sales increased to KEUR 444 in Q3-24 from KEUR 410 in Q2-24, or 8%. Compared to Q3-24, net sales were down by KEUR 473 from KEUR 917, or 52%.
· Gross profit in Q3-24 was KEUR 211, a decrease of 32% from KEUR 311 in Q2-24 and 39% from KEUR 348 in Q3-23. The gross margin was 46% in Q3-24, down from 76% in Q2-24 and up from 34% in Q3-23. The decline from Q2-24 was due to a change in product mix in sales and the rising prices of raw materials from berries.
· EBITDA in Q3-24 was KEUR - 299, compared to KEUR - 198 in Q2-24 and positive KEUR 2 in Q3-23. The reduction in EBITDA of KEUR 101 between Q2-24 and Q3-24 mainly stemmed from Board compensations booked in July and legal costs related to the Equity issue booked in Overheads. Adjusted for one-off costs related to the Rights issue, the EBITDA was KEUR - 187 in Q3-24.
· Financial expenses for Q3-25 were KEUR 327 due to significant costs related to guarantor commissions and fees related to the facilitation of the Rights issue.
· The net result for Q3-24 was negative with KEUR - 931 compared to KEUR - 558 in Q2-24 and KEUR - 317 in Q3-23.
· Cash flow from operations was negative, with KEUR -365 in Q3-24 compared to KEUR - 269 in Q2-24 and KEUR - 1 023 in Q3-23. The decrease in operating cash flow stems primarily from changes in working capital during the period and negative EBITDA.
· Eevia repaid in July a short-term loan from a Danish fund of KEUR 656, which was taken up in Q2-24.
· We executed a direct placement in September of 2,7 million shares as guarantee-commissions to guarantors.
· Eevia won a significant new customer in August, which placed quite quickly two orders of Feno-Myrtillus 25.
· We landed a significant order from a domestic customer of KEUR 90.
· We worked on reducing inventory in the quarter, but due to an out of specificaton delivery which we had to
take back, reprocess and then reinvoice in Q4-24, the inventory level did not come down for the quarter.
· A comprehensive turnaround plan was developed during September, and finalized and approved in October-November, forming a new strategic business plan for Eevia Health. Significant customer validations were acquired during October.
· After the period, a new Board was elected (November).
· We achieved the first commercially significant sales of Liquid berry sugars, a side stream product, to a Baltic company. Interest from other larger players followed and a market for these products is now identified.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          

Email: [email protected]                      

Telephone: +358 400 22 5967                         

This disclosure contains information that EEVIA HEALTH PLC must make public according to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication through the contact person's agency on November 29, 2024, at 16:30 CET.

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.

Eevia Health manufactures 100% organically certified plant extracts. Our commitment to sustainable and organic manufacturing practices, such as wild harvesting our raw materials and operating a modern green chemistry production facility, ensures the highest quality products for our customers.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. In June 2021, Eevia listed its shares on the Spotlight Stock Market in Sweden under the short name EEVIA.

To learn more, please visit  www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.